Neovacs SA
ALNEV
Company Profile
Business description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Contact
3-5, Impasse Reille
Paris75014
FRAT: +33 153109300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.30 | 4.50 | 0.05% |
| CAC 40 | 7,615.99 | 78.42 | 1.04% |
| DAX 40 | 23,641.58 | 372.57 | 1.60% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,758.99 | 0.95 | 0.01% |
| HKSE | 24,371.11 | 194.04 | 0.80% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,791.18 | 0.62 | 0.00% |
| NZX 50 Index | 12,446.05 | 21.43 | -0.17% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,559.80 | 4.30 | 0.05% |
| SSE Composite Index | 3,430.16 | 9.60 | 0.28% |